MIT Holdings Featured in Scientific American
MIT Holding, Inc. (OTCBB:MITD), was recently highlighted in an article that appeared in the Scientific American Magazine website. Dr. Thomas Kollars, MIT’s Chief Scientific Advisor as well as the Director of the BioDefense and Infectious Disease Laboratory, Georgia Southern University (GSU), highlights the company’s ongoing collaborative research and development of the PROVECTOR™ with GSU and MEVLABS, Inc. The PROVECTOR, invented by Dr. Kollars, is a small dispensable device designed to stop the development of pathogens and parasites found in mosquitoes that carry deadly infectious diseases such as malaria, dengue fever, and West Nile virus. To read the article, visit the following link: http://www.sciam.com/article.cfm?id=malaria-flower-dengue-disease.
Titled “A ‘Flower’ That Delivers Disease-Killing Treatments to Mosquitoes,” the article highlights the ways in which the PROVECTOR is designed to use visual, olfactory, and chemical signals to entice mosquitoes to ingest antimalarial and antiviral treatments that inhibit the development of the pathogens. “There’s an alternative on the horizon that promises to be safer and cheaper by zapping the germs while sparing the mosquitoes,” author Larry Greenemeier writes. “The technology is hidden in an artificial flower designed to attract mosquitoes and treat them with pathogen-killing drugs that allow the insects to live and continue to perform important functions such as pollinating flowers and serving as food for animals and other insects.”
“Scientific American is widely read and respected by both the lay and scientific communities,” said Dr. Kollars. “We have been approached by a number of medical professionals from other countries interested in collaborating with us. We will leverage our technology and international contacts to seek additional funding from private foundations and the Federal Government to provide the PROVECTOR to over 500 million people. I’m honored and humbled to have the opportunity to help improve the lives of so many people.”
“We are delighted to be recognized in Scientific American,” said William Parker, Chief Executive Officer of MIT Holding. “We believe the PROVECTOR offers a different approach to current methods of combating infectious diseases. Current methods of stopping the spread of infectious disease, which include costly preventative medicines with serious side effects and emerging drug-resistance and the reduction of effective pesticides due to insecticide resistant mosquitoes, are not working and leaving millions of people vulnerable to getting infected. We look forward to gaining visibility of our PROVECTOR initiative and commercializing the product in countries that need help in the fight against infectious disease.”
About Scientific American
Scientific American is the world’s leading source and authority for science and technology information. Since 1845, Scientific American’s magazines have chronicled the world’s major science and technology innovations and discoveries. Published in nineteen foreign language editions with a total circulation of more than one million worldwide, Scientific American reaches business executives, opinion leaders, policy makers, academics, and well-educated general consumers. Scientific American is also a leading online science, health, and technology destination (www.SciAm.com), providing the latest news and exclusive features to more than 1,700,000 visitors monthly, and distributing its content through podcasts and other digital services.
Scientific American is wholly owned by Macmillan (formerly Holtzbrinck Publishers), which publishes high-quality academic and scholarly books, educational materials, fiction and non-fiction, children’s books, audio books, magazines, and journals in print and digital formats. Other Macmillan publishing companies include: St. Martin’s Press; Farrar, Straus & Giroux; Henry Holt and Company; Tor Books; Picador; Bedford/St. Martin’s; Worth Publishers; W.H. Freeman and Company; and Palgrave Macmillan.
Macmillan is wholly owned by the Verlagsgruppe Georg Von Holtzbrinck GmbH, which is a private, family-owned company, headquartered in Stuttgart, Germany, and is active in more than eighty countries, publishing works in print and electronic media.
About MIT Holding Inc.
Through its wholly owned subsidiaries, MIT distributes wholesale pharmaceuticals in the United States and overseas, administers intravenous infusions and, in Georgia, operates ambulatory centers where therapies are administered and sells and rents home medical equipment. MIT is based in Savannah, Georgia and operates an ambulatory care center in Savannah. MIT is establishing relationships with government agencies and distributors outside the United States in order to purchase and sell pharmaceuticals internationally. MIT has initiated government contacts to obtain the necessary approvals to import pharmaceutical products into the Dominican Republic, Haiti, Costa Rica, the Bahamas, Argentina, and Brazil. MIT’s domestic wholesale pharmaceutical distribution is conducted through Medical Infusion Technologies, Inc., which sells pharmaceuticals to end-users and other wholesalers in the U.S. MIT plans to form a subsidiary to distribute pharmaceuticals to locations outside of the United States and another subsidiary for sales to institutions, such as hospitals and nursing homes. MIT provides infusion pharmacy services through its pharmacy in Savannah, Georgia. The licensed pharmacy can dispense infusible and non-infusible prescription pharmaceuticals to treat a wide range of chronic and acute health conditions. The home medical equipment division carries a wide variety of durable medical equipment and supplies for purchase or lease. The division maintains inventory and can rapidly obtain a wide variety of home medical equipment products to match almost any request.
Forward-Looking Statements
Some of the information contained in this release contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities and Exchange Act of 1934 the “Exchange Act”), which mean that they relate to events or transactions that have not yet occurred, our expectations or estimates for our future operations, our growth strategies or business plans or other facts that have not yet occurred. These statements can be identified by the use of forward-looking terminology such as “might,”"may,”"could,”"expect,”"anticipate,”"estimate,”"likely,”"intend,”"believe,” or “continue” or the negative thereof or other variations thereon or comparable terminology. For an explanation of some of the risks and uncertainties facing MIT and its investors, please see our most recent prospectus on file with the Securities Exchange Commission. The risk factors contained therein should be considered by prospective investors for their potential impact on forward-looking statements included in this release. These important factors, among others that might not be listed, may cause actual results to differ materially and adversely from the results expressed or implied by the forward-looking statements. We caution investors that such discussions of important risks and uncertainties are not exclusive, and our business may be subject to other risks and uncertainties, which are not detailed there.
Investors are cautioned not to place undue reliance on our forward-looking statements. We make forward-looking statements as of the date of this release, and we assume no obligation to update the forward-looking statements after the date hereof whether as a result of new information or events, changed circumstances, or otherwise, except as required by law.